Showing 1 posts of 1 posts found.
Helsinn is on track to complete construction of a new manufacturing plant for cytotoxic active pharmaceutical ingredients in Biasca, Switzerland, …
Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial
Highlighting the value of lab research for healthcare innovation
Capital Dynamics invests €14m in Italian community healthcare platform CareHub
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO